Breaking News, Collaborations & Alliances

Enteris BioPharma Receives $10M Milestone from Cara Therapeutics

Third milestone payment related to the development of Oral KORSUVA.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

The contract development and manufacturing organization (CDMO) Enteris BioPharma received a $10 million milestone payment from Cara Therapeutics related to the license agreement for the Peptelligence oral formulation technology utilized in Oral KORSUVA—the oral formulation of Cara’s first-in-class KOR agonist, CR845/difelikefalin. Enteris is entitled to retain $3.9 million of this payment per the contractual splits agreed to in the Enteris acquisition agreement with its parent, SWK Holding...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters